We thank Drs. Struthers and Lang for their thoughtful comments on the multiple mechanisms that may underlie the association of circulating natriuretic peptides with endothelial function measures. The authors note that natriuretic peptide levels correlate positively with increased vascular stiffness, subclinical myocardial ischemia, and congestive heart failure. [1] [2] [3] Because the latter 2 conditions are in turn associated with endothelial dysfunction, higher natriuretic peptide levels may be associated with lower flow-mediated dilation (FMD).
In our community-based sample, 4 we observed a directionality of association opposite to that postulated by Drs Struthers and Lang, ie, plasma atrial natriuretic peptide was positively related to endothelial function as assessed by FMD. The cross-sectional nature of our study does not permit us to infer whether elevated natriuretic peptide levels promote increased FMD. Nonetheless, our observations are consistent with the in vitro demonstration of a vascular smooth relaxant effect for natriuretic peptides. 5 Additionally, in studies of healthy volunteers, infusion of natriuretic peptides increases FMD. 6 We submit that the contrasting directionality of associations observed in our study versus some other reports 1-3 may be due to differences in the study samples. We studied a large communitybased sample with a low prevalence of cardiovascular disease and diabetes, whereas the studies cited by the authors evaluated referral samples with a greater prevalence of risk factors and/or cardiovascular disease. Overall, we believe that the directionality of the relation between natriuretic peptide levels and endothelial function merits further study.
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